<DOC>
	<DOCNO>NCT00004998</DOCNO>
	<brief_summary>The purpose study see two different dos AG1549 plus anti-HIV drug safe effective HIV-infected patient take anti-HIV drug .</brief_summary>
	<brief_title>Safety Effectiveness New Anti-HIV Drug ( AG1549 ) Combination With Other Anti-HIV Drugs HIV-Infected Patients</brief_title>
	<detailed_description>[ Note : As 2/28/2001 , due toxicity study concern safety , site notify need discontinue patient capravirine/placebo arm continue patient background therapy switch patient new therapy , deem appropriate investigator . ] Patients randomize receive one two dos AG1549 plus Viracept ( nelfinavir ) plus Combivir ( zidovudine/lamivudine ) . Patients remain assigned therapy 48 week , follow-up visit 28 35 day last dose study medication . Blood sample take regularly quantify HIV-1 RNA , CD4 CD8 count , peripheral blood mononuclear cell ( PBMC ) , AG1549 , Viracept , M8 plasma concentration . Physical exam , safety assessment , test also do throughout study . On Day 8 end Week 48 , pharmacokinetic sample collect 0 , 0.5 , 1.0 , 1.5 , 2.0 , 2.5 , 3.0 , 4.0 , 6.0 , 8.0 , 12.0 hour postdose . At end Weeks 4 , 8 , 16 , 24 , 36 , pharmacokinetic sample take prior dose 2 4 hour post-dose .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nelfinavir</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<mesh_term>Anti-Retroviral Agents</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible : Are HIVpositive . Are least 18 year old . Have CD4 cell count 50 cells/mm3 . Have HIV level 5000 copies/ml . Exclusion Criteria Patients eligible : Have ever take follow antiHIV drug : nonnucleoside reverse transcriptase inhibitor ( NNRTIs ) , AG1549 , Viracept , zidovudine , lamivudine , Combivir . Other antiHIV drug allow take 30 day last dose take 6 month prior study entry . Have take experimental drug within 28 day study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2001</verification_date>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>HIV Protease Inhibitors</keyword>
	<keyword>Lamivudine</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Nelfinavir</keyword>
	<keyword>Combivir</keyword>
</DOC>